The effects of a new angiotensin receptor antagonist, eprosartan (200 or 300 mg b.i.d.) and enalapril (5-20 mg u.i.d.) on cough and blood pressure were compared in a 26-week, double-blind, randomised, parallel-group, multicentre, international study involving 528 patients with hypertension. Uptitration of doses was based on clinic blood pressure measurements during the first 12 weeks, after which hydrochlorothiazide (12.5-25 mg/day) could be added. The frequency and intensity of cough was assessed by a standardised questionnaire administered at each clinic visit. The primary end-point was the incidence of persistent, dry cough not due to upper respiratory infection; change in sitting diastolic blood pressure and overall incidence of cough were secondary end-points. During the first 12 weeks of double-blind therapy, enalapril treatment was associated
Introduction
Angiotensin-coverting enzyme (ACE)-inhibitors are useful in treating hypertension, heart failure, and renal impairment, but are most often discontinued because of the development of a persistent, dry cough, the prevalence of which has been reported as high as 25-69%. [1] [2] [3] [4] [5] [6] Unlike ACE-inhibitors, angiotensin II receptor antagonists do not inhibit bradykinin degradation in vitro, and have been associated with a lower incidence of cough in carefully selected patients who demonstrated the cough response to an ACE-inhibitor. [7] [8] [9] [10] Eprosartan is a new, highlyselective non-peptide, non-biphenyl, non-tetrazole angiotensin II receptor blocker with few effects on the cyctochrome P 450 system. 11 This paper describes the results of a large clinical study designed to compare the effects of eprosartan and enalapril on cough and blood pressure (BP) in unselected hypertensive patients. with a 3.45-fold higher risk of definite cough (14/261 vs 4/259, P ‫؍‬ 0.018). Overall cough incidence (from spontaneous reports from patients, or investigator's observation) was also more frequent with enalapril, as compared to eprosartan. Both agents reduced blood pressure significantly compared to baseline, although the eprosartan-treated group had a slightly higher response rate (defined as sitting diastolic blood pressure Ͻ90 mm Hg, or at least a 10 mm Hg reduction from baseline), both at end of titration (70.3% vs 62.6%, P Ͻ 0.05) and after 26 weeks (81.7% vs 73.5%, P ‫؍‬ 0.018). These data suggest that, in unselected hypertensive patients, eprosartan is associated with less cough and a somewhat higher responder rate than enalapril.
Patients and methods

Study design
This 41-centre, international double-blind, doubledummy, parallel-group study consisted of three treatment periods: a 3-to 5-week single-blind placebo run-in ('baseline') period, an 18-week doubleblind titration period, and an 8-week maintenance period. Initially, patients were randomised to receive either eprosartan 200 mg twice daily or enalapril 5 mg once daily. At 3-week intervals, the office blood pressure was measured and the dose titrated as needed to a maximum dosage of 300 mg twice daily eprosartan or 20 mg once daily enalapril. At the end of week 12, the maximum doses of doubleblind medication were supplemented with HCTZ 12.5 mg once daily, and increased if needed to a maximum of 25 mg daily.
This study was conducted in accordance with the Declaration of Helsinki as amended. The protocol and informed consent signed by each participant were approved by the Institutional Review Board or Ethics Committee at each study site.
Patients
Patients were eligible if they were at least 18 years of age and had essential hypertension. Premenopausal women of childbearing potential were required to be using hormonal, barrier, or intrauterine contraception.
Patients with secondary forms of hypertension, advanced hypertensive retinopathy, average sitting systolic blood pressure (SitSBP) Ͼ200 mm Hg, advanced atrioventricular conduction defects, ventricular tachyarrhythmias requiring therapy, bradycardia, prior myocardial infarction or cerebrovascular accident within the past 90 days, congestive heart failure being treated with ACE inhibitors or diuretics, angina being treated with nitrates, betablockers, or calcium channel blockers, unstable diabetes mellitus, or presence of clinically significant renal or hepatic disease or another concurrent severe disease, were excluded. Patients were also excluded if they had conditions which could interfere with the assessment of cough: emphysema, asthma or chronic bronchitis, or upper respiratory infection within 2 weeks of screening. Use of anticoagulants or another investigational drug within 30 days of enrolment, chronic sympathomimetic amine or nonsteroidal anti-inflammatory drugs (other than low-dose aspirin) within 7 days of enrolment, and concomitant use of antidepressants or medications known to affect blood pressure or cough were not allowed.
Assessments of cough and blood pressure
A pulmonary assessment (physician's physical examination of the chest by auscultation and percussion, if abnormal) was performed at screening, at randomisation, at weeks 6 and 12 of the titration phase, and at the end of the maintenance phase. No pulmonary function testing was performed. The presence and character of cough were assessed by the investigator regarding type, duration, severity, frequency, and probable cause of cough. Cough was categorised according to a hierarchy of severity as definite, probable, possible, or a 'tickle in throat'. At each visit, the patient completed a quality-of-life questionnaire, which included a five-point tolerability rating scale of both frequency (never, seldom, occasional, frequent, or constant) and severity for each of 10 commonly-experienced adverse effects with antihypertensive medications (one of which was cough). Cough that occurred at any time during the trial was recorded as an adverse experience. Blood pressure and heart rate were measured in triplicate at each visit during the four study periods, according to standard techniques.
Statistical analyses
The primary end-point was definite cough of interest, defined as the incidence of persistent, non-productive (dry) cough associated with treatment and not due to an upper respiratory infection as judged by the investigator. The cough must have been present for at least 2 weeks unless the patient voluntarily discontinued medication because of coughing. Maximum cough was defined as the sum of definite, probable, and possible cough, and tickle in throat. Antihypertensive efficacy was measured at trough as the mean change from baseline in sitting and standing systolic blood pressure (SBP) and diastolic blood pressure (DBP). Responders were patients whose SitDBP was less than either 90 mm Hg, or 100 mm Hg and had decreased from baseline by at least 10 mm Hg.
Baseline values were obtained at the last visit of the placebo run-in period, before randomisation. For blood pressure only, baseline was the mean of the last two visits prior to randomisation. Comparisons at baseline with respect to categorical demographic and clinical characteristics were performed using the chi-square technique with adjustment for sampling differences across centres. For continuous variables, baseline differences were assessed by analysis of variance (PROC GLM in SAS), which included terms for centre, medication regimen, and interaction with centre. Centralised data collection and statistical analysis were performed by full-time employees of the sponsor (SmithKline Beecham Pharmaceuticals, Inc, Philadelphia, PA, USA).
For the categorical variables of cough incidence, cough severity, and response rate, comparisons between the eprosartan and enalapril regimens during the double-blind periods were performed using a Cochran-Mantel-Haenszel (CMH) statistic adjusting for centre interaction with regimen, which was assessed with the Breslow-Day test (PROC FREQ in SAS). For vital signs, an analysis of variance was performed at each visit, which included terms for centre, medication regimen, and regimen-by-centre interaction. If the latter was not significant (P Ͼ 0.10), it was removed from the model. Subgroups of age, gender, race, prior use of antihypertensives, and baseline severity of hypertension were compared using similar techniques for cough, blood pressure, and response rate.
Results
Patient demographics and treatment regimens
The demographic and clinical characteristics of the patients are shown in Table 1 ; there were no significant differences between groups in any of these parameters. In the eprosartan group, 138 patients were titrated to the maximum dose of 300 mg twice daily, whereas 151 patients in the enalapril group were titrated to the maximum dose of 20 mg once daily. In each group, 81 patients initially received HCTZ 12.5 mg once daily, and then 51 patients from the eprosartan group and 50 patients from the enalapril group received the maximum dose plus HCTZ 25 mg once daily.
Incidence of cough
A significantly higher incidence of definite cough was found in the enalapril group prior to the introduction of HCTZ, the primary timepoint of interest, when compared with the eprosartan group 415 (Figure 1 ). Definite cough occurred in 14 (5.4%) patients randomised to enalapril and four (1.5%) patients receiving eprosartan; the incidence of definite cough during placebo-treatment was 1.9% or 0.8% in the groups subsequently treated with eprosartan or enalapril, respectively. Patients randomised to enalapril were 3.45 (95% CI 1.26-10.0) times more likely to experience definite cough than patients receiving eprosartan. During the entire 26-week double-blind treatment period, patients in the enalapril group were 3.85 times (95% CI 1.48-10.3) more likely to experience definite cough: the incidences of definite cough were 6.1% and 1.5% in the enalapril and eprosartan groups, respectively. Similar results were obtained in analyses of 'maximum cough' during monotherapy, with enalapril being associated with a 1.41 (95% CI: 1.06-1.89) times higher risk of 'maximum cough' than eprosartan. Results from patient questionnaires also showed that enalapril was associated with a higher rate of subjectively-reported cough, whether assessed as 'definite cough' or 'maximum cough' (22 vs 13%, 2 = 8.15; P = 0.01). Seven patients randomised to enalapril treatment discontinued participation because of cough; only two patients randomised to eprosartan stopped due to this perceived adverse effect; the cough resolved in all patients after discontinuing study medication.
There were no significant differences in demographic characteristics of patients who coughed, compared to those who did not report cough, with the exception of gender and smoking history. Women were significantly more likely to report cough ('maximum cough') during the monotherapy treatment period than were men (odds ratio = 1.86, 95% CI: 1.15-3.0): a similar trend was seen for the end-point of 'definite cough'. Similarly, there was a trend for smokers to report more 'maximum cough' than non-smokers (odds ratio = 1.72, 95% CI: 0.95-3.12), which was also seen for 'definite cough'.
Data were also collected regarding adverse experiences which might have contributed to cough, but were not attributed to 'definite cough', eg, viral or upper respiratory tract infection, or pharyngitis. In each case, the incidence of symptoms which might have been potential confounders for 'definite cough' were found less frequently in the eprosartan-treated group: any adverse experience (76% vs 81%), pharyngitis (17% vs 24%), rhinitis (12% vs 16%), upper respiratory tract infection (12% vs 16%), viral infection (3% vs 6%).
Analyses of blood pressure
Eprosartan and enalapril produced similar mean changes from baseline for SitDBP, SitSBP, StaDBP, and StaSBP when evaluated at the end of the titration phase, maintenance phase, or at the end of study, when SitDBP and SitSBP were decreased by 12.9 mm Hg and 15.5 mm Hg, respectively, in the eprosartan group; whereas in the enalapril group, these measures decreased by 11.9 mm Hg and 14.7 mm Hg, respectively. Analysis of variance revealed no significant difference between the two treatments on sitting or standing vital signs at the end of study.
Response rate
A somewhat higher percentage of eprosartan-treated patients responded to treatment when measured at the end of the titration and maintenance phases ( Table 2 ). The response rate at the end of study was significantly higher in the eprosartan group with 81.7% of eprosartan-treated patients vs 73.4% of enalapril-treated patients (P Ͻ 0.05). In pre-specified subgroup analyses, the response rate at end of titration in black patients was 81.0% for the eprosartan group and 57.9% for the enalapril group (P Ͻ 0.05). The differences among Caucasian patients were not significant.
There were no significant differences between treatment groups in changes in quality of life measurements (using the General Well Being Index), laboratory parameters, serious adverse events, or pre-specified changes in vital signs of concern.
Discussion
The results from this study demonstrate that eprosartan produces a lower incidence of persistent, nonproductive cough than enalapril in patients with essential hypertension. This type of cough has emerged as an important side effect of ACE inhibitors which limits their utility in many patients. During this 26-week double-blind trial in patients not selected for previous cough with ACE-inhibitors, the incidence of definite, persistent, non-productive cough was 1.5% for patients treated with eprosartan, vs 5.4% with enalapril; a similar pattern was seen in secondary analyses of 'maximum cough'. Although the 5.4% prevalence of ACE-inhibitorassociated cough is far lower than that reported from uncontrolled trials, it is not much lower than the 7.7% reported in an unselected consecutive series of hypertensive patients which used dechallenge/rechallenge methodology to be sure that the cough was associated with ACE-inhibitor therapy. 12 Yeo and Ramsay 3 have clearly shown that the prevalence of cough with ACE-inhibitors is inversely proportional to the amount of work expended to detect and ascribe a cause to it. In this study, patient-reported 'definite cough' was unchanged from baseline levels prior to receiving eprosartan, and the incidence of patient-reported 'maximum cough' actually decreased from baseline while on treatment.
Both eprosartan and enalapril produced similar reductions in DBP and SBP; however, a significantly greater percentage of patients treated with eprosartan responded to treatment. This observed difference may be due to the relatively short elimination half-life of enalapril, the relatively low trough-peak ratio of once-daily enalapril, the twice-daily administration of eprosartan, or a combination of these and other factors. The probability of responding to treatment was approximately 13% greater for the eprosartan group than for patients treated with enalapril.
Subgroup analyses of patients according to age, gender, race, prior use of hypertensive drugs, or severity of hypertension confirmed the higher incidence of cough with enalapril, and suggested that eprosartan has a more uniform effect on blood pressure across the patient population, as differences in responder rate between the two treatments were consistent. When patients were subgrouped according to race, Black patients treated with eprosartan had a significantly greater response rate than those treated with enalapril: at the end of titration, the response rate for enalapril was 57.9% of Black patients and 85.3% of Caucasian patients; whereas for eprosartan, the responder rates were 81.0% and 87.5% for Black and Caucasian patients, respectively.
In this study, enalapril was found to be less effective for lowering blood pressure in Black patients than in other races, as has been seen previously with this and other ACE-inhibitors. 13, 14 For example, when 1-year captopril monotherapy was compared with drugs from five other antihypertensive drug classes, the ACE inhibitor was the least effective. 13 Only 32% of Black patients under 60 years of age had their blood pressures controlled by captopril, whereas captopril was identical to placebo in Black patients over 60 years of age. 15 In addition to the lower efficacy of ACE inhibitors in Black patients, there is a greater risk for both cough (2.6-fold) and angioedema (4.5-fold) associated with ACE-inhibitors in Blacks, which may be independent of dose. 12, 15 The mechanisms accounting for why Black patients are less responsive to ACE inhibitors and have a greater risk of ACE inhibitor-associated adverse effects are unknown.
In summary, patients receiving eprosartan had a statistically significantly lower risk of cough than did patients receiving enalapril, a result that was consistent with the results of patient self-reported cough and patient withdrawals due to cough. Both agents lowered blood pressure to a similar degree; however, patients treated with eprosartan had a higher response rate. Other than cough and pharyngitis (a symptom which could have been interpreted by patients as 'tickle in the throat') occurring more frequently in enalapril-treated patients, both agents had similar adverse experience and safety profiles. Thus, eprosartan represents an attractive alternative to enalapril for treating patients with essential hypertension.
